publication . Article . Other literature type . 2019

Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers

Gemma Salvadó; José Luis Molinuevo; Anna Brugulat-Serrat; Carles Falcon; Oriol Grau-Rivera; Marc Suárez-Calvet; Javier Pavia; Aida Niñerola-Baizán; Andrés Perissinotti; Francisco Lomeña; ...
Open Access English
  • Published: 01 Mar 2019 Journal: Alzheimer’s Research & Therapy (issn: 1758-9193, Copyright policy)
  • Publisher: BMC
Abstract
Background The Centiloid scale has been developed to standardize measurements of amyloid PET imaging. Reference cut-off values of this continuous measurement enable the consistent operationalization of decision-making for multicentre research studies and clinical trials. In this study, we aimed at deriving reference Centiloid thresholds that maximize the agreement against core Alzheimer’s disease (AD) cerebrospinal fluid (CSF) biomarkers in two large independent cohorts. Methods A total of 516 participants of the ALFA+ Study (N = 205) and ADNI (N = 311) underwent amyloid PET imaging ([18F]flutemetamol and [18F]florbetapir, respectively) and core AD CSF biomarker...
Subjects
free text keywords: AD pathophysiology, Biomarker concordance, Threshold, Positivity, Preclinical, Early detection, Neurosciences. Biological psychiatry. Neuropsychiatry, RC321-571, Neurology. Diseases of the nervous system, RC346-429, Research, Positron emission tomography, Phosphorylated tau, Biomarker categorization
Funded by
NIH| Alzheimers Disease Neuroimaging Initiative
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 1U01AG024904-01
  • Funding stream: NATIONAL INSTITUTE ON AGING
,
CIHR
Project
  • Funder: Canadian Institutes of Health Research (CIHR)
,
EC| BioALFA
Project
BioALFA
The effect of pro-aging and pro-youthful blood factors in normal ageing and Alzheimer’s disease: a multimodal approach
  • Funder: European Commission (EC)
  • Project Code: 752310
  • Funding stream: H2020 | MSCA-IF-EF-ST
42 references, page 1 of 3

Villemagne, VL, Burnham, S, Bourgeat, P, Brown, B, Ellis, KA, Salvado, O. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol. 2013; 12: 357-367 [PubMed] [DOI]

Vos, SJB, Xiong, PC, Visser, PJ, Ms, MSJ, Hassenstab, J, Grant, EA. Preclinical Alzheimer’s disease and its outcome: a longitudinal cohort study. Lancet Neurol. 2013; 12: 957-965 [OpenAIRE] [PubMed] [DOI]

Shaw, LM, Vanderstichele, H, Knapik-Czajka, M, Clark, CM, Aisen, PS, Petersen, RC. Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Ann Neurol. 2009; 65: 403-413 [OpenAIRE] [PubMed] [DOI]

Ikonomovic, MD, Buckley, CJ, Heurling, K, Sherwin, P, Jones, PA, Zanette, M. Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection. Acta Neuropathol Commun. 2016; 4: 130 [OpenAIRE] [PubMed] [DOI]

Seppälä, TT, Nerg, O, Koivisto, AM, Rummukainen, J, Puli, L, Zetterberg, H. CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings. Neurol. 2012; 78: 1568 LP-1561575 [OpenAIRE] [DOI]

Jack, CR, Bennett, DA, Blennow, K, Carrillo, MC, Dunn, B, Haeberlein, SB. NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018; 14: 535-562 [OpenAIRE] [PubMed] [DOI]

Sperling, RA, Aisen, PS, Beckett, LA, Bennett, DA, Craft, S, Fagan, AM. Toward defining the preclinical stages of Alzheimer’s disease. Alzheimers Dement. 2011; 7: 280-292 [OpenAIRE] [PubMed] [DOI]

Sperling, RA, Mormino, EC, Johnson, KA. The evolution of preclinical Alzheimer’s disease: implications for prevention trials. Neuron. 2014; 84: 608-622 [OpenAIRE] [PubMed] [DOI]

Fagan, AM, Mintun, MA, Mach, RH, Lee, SY, Dence, CS, Shah, AR. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta 42 in humans. Ann Neurol. 2006; 59: 512-519 [OpenAIRE] [PubMed] [DOI]

Fagan, AM, Mintun, MA, Shah, AR, Aldea, P, Roe, CM, Mach, RH. Cerebrospinal fluid tau and ptau181increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer’s disease. EMBO Mol Med. 2009; 1: 371-380 [OpenAIRE] [PubMed] [DOI]

Grimmer, T, Riemenschneider, M, Förstl, H, Henriksen, G, Klunk, WE, Mathis, CA. Beta amyloid in Alzheimer’s disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol Psychiatry. 2009; 65: 927-934 [OpenAIRE] [PubMed] [DOI]

Forsberg, A, Almkvist, O, Engler, H, Wall, A, Langstrom, B, Nordberg, A. High PIB retention in Alzheimers disease is an early event with complex relationship with CSF biomarkers and functional parameters. Curr Alzheimer Res. 2010; 7: 56-66 [OpenAIRE] [PubMed] [DOI]

Jagust, WJ, Landau, SM, Shaw, LM, Trojanowski, JQ, Koeppe, RA, Reiman, EM. Relationships between biomarkers in aging and dementia. Neurol. 2009; 73: 1193-1199 [DOI]

Koivunen, J, Pirttilä, T, Kemppainen, N, Aalto, S, Herukka, SK, Jauhianen, AM. PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid β-amyloid in mild cognitive impairment. Dement Geriatr Cogn Disord. 2008; 26: 378-383 [OpenAIRE] [PubMed] [DOI]

Landau, SM, Lu, M, Joshi, AD, Pontecorvo, M, Mintun, MA, Trojanowski, JQ. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid. Ann Neurol. 2013; 74: 826-836 [OpenAIRE] [PubMed] [DOI]

42 references, page 1 of 3
Abstract
Background The Centiloid scale has been developed to standardize measurements of amyloid PET imaging. Reference cut-off values of this continuous measurement enable the consistent operationalization of decision-making for multicentre research studies and clinical trials. In this study, we aimed at deriving reference Centiloid thresholds that maximize the agreement against core Alzheimer’s disease (AD) cerebrospinal fluid (CSF) biomarkers in two large independent cohorts. Methods A total of 516 participants of the ALFA+ Study (N = 205) and ADNI (N = 311) underwent amyloid PET imaging ([18F]flutemetamol and [18F]florbetapir, respectively) and core AD CSF biomarker...
Subjects
free text keywords: AD pathophysiology, Biomarker concordance, Threshold, Positivity, Preclinical, Early detection, Neurosciences. Biological psychiatry. Neuropsychiatry, RC321-571, Neurology. Diseases of the nervous system, RC346-429, Research, Positron emission tomography, Phosphorylated tau, Biomarker categorization
Funded by
NIH| Alzheimers Disease Neuroimaging Initiative
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 1U01AG024904-01
  • Funding stream: NATIONAL INSTITUTE ON AGING
,
CIHR
Project
  • Funder: Canadian Institutes of Health Research (CIHR)
,
EC| BioALFA
Project
BioALFA
The effect of pro-aging and pro-youthful blood factors in normal ageing and Alzheimer’s disease: a multimodal approach
  • Funder: European Commission (EC)
  • Project Code: 752310
  • Funding stream: H2020 | MSCA-IF-EF-ST
42 references, page 1 of 3

Villemagne, VL, Burnham, S, Bourgeat, P, Brown, B, Ellis, KA, Salvado, O. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol. 2013; 12: 357-367 [PubMed] [DOI]

Vos, SJB, Xiong, PC, Visser, PJ, Ms, MSJ, Hassenstab, J, Grant, EA. Preclinical Alzheimer’s disease and its outcome: a longitudinal cohort study. Lancet Neurol. 2013; 12: 957-965 [OpenAIRE] [PubMed] [DOI]

Shaw, LM, Vanderstichele, H, Knapik-Czajka, M, Clark, CM, Aisen, PS, Petersen, RC. Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Ann Neurol. 2009; 65: 403-413 [OpenAIRE] [PubMed] [DOI]

Ikonomovic, MD, Buckley, CJ, Heurling, K, Sherwin, P, Jones, PA, Zanette, M. Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection. Acta Neuropathol Commun. 2016; 4: 130 [OpenAIRE] [PubMed] [DOI]

Seppälä, TT, Nerg, O, Koivisto, AM, Rummukainen, J, Puli, L, Zetterberg, H. CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings. Neurol. 2012; 78: 1568 LP-1561575 [OpenAIRE] [DOI]

Jack, CR, Bennett, DA, Blennow, K, Carrillo, MC, Dunn, B, Haeberlein, SB. NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018; 14: 535-562 [OpenAIRE] [PubMed] [DOI]

Sperling, RA, Aisen, PS, Beckett, LA, Bennett, DA, Craft, S, Fagan, AM. Toward defining the preclinical stages of Alzheimer’s disease. Alzheimers Dement. 2011; 7: 280-292 [OpenAIRE] [PubMed] [DOI]

Sperling, RA, Mormino, EC, Johnson, KA. The evolution of preclinical Alzheimer’s disease: implications for prevention trials. Neuron. 2014; 84: 608-622 [OpenAIRE] [PubMed] [DOI]

Fagan, AM, Mintun, MA, Mach, RH, Lee, SY, Dence, CS, Shah, AR. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta 42 in humans. Ann Neurol. 2006; 59: 512-519 [OpenAIRE] [PubMed] [DOI]

Fagan, AM, Mintun, MA, Shah, AR, Aldea, P, Roe, CM, Mach, RH. Cerebrospinal fluid tau and ptau181increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer’s disease. EMBO Mol Med. 2009; 1: 371-380 [OpenAIRE] [PubMed] [DOI]

Grimmer, T, Riemenschneider, M, Förstl, H, Henriksen, G, Klunk, WE, Mathis, CA. Beta amyloid in Alzheimer’s disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol Psychiatry. 2009; 65: 927-934 [OpenAIRE] [PubMed] [DOI]

Forsberg, A, Almkvist, O, Engler, H, Wall, A, Langstrom, B, Nordberg, A. High PIB retention in Alzheimers disease is an early event with complex relationship with CSF biomarkers and functional parameters. Curr Alzheimer Res. 2010; 7: 56-66 [OpenAIRE] [PubMed] [DOI]

Jagust, WJ, Landau, SM, Shaw, LM, Trojanowski, JQ, Koeppe, RA, Reiman, EM. Relationships between biomarkers in aging and dementia. Neurol. 2009; 73: 1193-1199 [DOI]

Koivunen, J, Pirttilä, T, Kemppainen, N, Aalto, S, Herukka, SK, Jauhianen, AM. PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid β-amyloid in mild cognitive impairment. Dement Geriatr Cogn Disord. 2008; 26: 378-383 [OpenAIRE] [PubMed] [DOI]

Landau, SM, Lu, M, Joshi, AD, Pontecorvo, M, Mintun, MA, Trojanowski, JQ. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid. Ann Neurol. 2013; 74: 826-836 [OpenAIRE] [PubMed] [DOI]

42 references, page 1 of 3
Powered by OpenAIRE Research Graph
Any information missing or wrong?Report an Issue